Ultimate Immune Support System
$214.95
The Ultimate Immune Support System provides comprehensive support for optimizing the body’s natural immune response, a healthy inflammatory response and the ability to neutralize oxidative stress. † †Results May Vary.
Ultimate Immune Support System
Extra Strength
The Ultimate Immune Support System provides comprehensive support for optimizing the body’s natural immune response, a healthy inflammatory response and the ability to neutralize oxidative stress.
RELATED: Calculate Your Immune System Function
The Ultimate Support System includes the following products.
ACS 200 Extra Strength
ACS 200 Extra Strength provides 200 parts per million of uniquely energized sliver molecules suspended in ultra-pure, deionized water; providing support for healthy immune and inflammatory responses.
ACZ nano Extra Strength
Heavy metal toxicity suppresses immune function and prevents healing.
ACZ Nano Zeolite Extra Strength provides daily support for the body’s natural detoxification process; an integral facet of overall health and wellbeing.
ACG Glutathione Extra Strength
Low Glutathione levels are proven to make us susceptible to chronic illness. The latest research shows that nearly all chronically ill patients suffer from Glutathione deficiency.
ACG Glutathione Extra Strength promotes the body’s ability to neutralize free radicals and reduce oxidative stress; the foundation of overall health and wellbeing.
ACN neuro Extra Strength
ACN Neuro Extra Strength is formulated to promote healthy cognitive function; supporting increased focus, concentration and improved mental alertness.
†Results may vary.
ACS 200 Extra Strength Ingredients
Silver (Elemental Silver)
Other Ingredients: Ultra-Pure Deionized Water
ACG Glutathione Extra Strength Ingredients
S-Acetyl-L-Glutathione, N-Acetyl L-Cysteine (NAC), Acetyl L-Carnitine, L-Glutamine, L-Glutathione Tripeptides (Reduced), Lipoic Acid (R-Fraction), TMG (trimethylglycine),Organic Peppermint (leaves) (Mentha x piperita), Ascorbic Acid.
Other Ingredients: Ultra-Pure Deionized Water
ACN Neuro Extra Strength Ingredients
Alpha-glycerophosphocholine (Alpha-GPC), CDP-choline (citicoline), Bacopa (leaves) (Bacopa monnieri), L-Theanine, Ginseng (root) (Panax ginseng), Sage (leaves) (Salvia officinalis), Turmeric (root) (Curcuma longa), Ginkgo (leaves) (Ginkgo biloba), Magnesium, Zinc, Organic Peppermint (leaves) (Mentha x piperita)
Other Ingredients: Ultra-Pure Deionized Water
ACZ Nano Extra Strength Ingredients
Activated Sub-micronized Zeolite.
Other Ingredients: Ultra-Pure Deionized Water
* % Daily value not established
While optimal dosage may vary based on the individual, we recommend beginning with the standard dose of 6 sprays of each formula/twice daily and gradually increasing to the higher dose of 12 sprays of each formula/twice daily.
The Ultimate Immune Support System Extra Strength formulas work synergistically and should be taken together. Take each formula individually by mouth one right after the other. Formulas can be taken 2 – 3 times daily. For optimal results, we recommend not eating or drinking for 2 minutes after taking the formulas. Take the sprays daily to achieve optimal health.
4 oz formulas: Provides 30 days of support when administered at the higher dose (12 sprays, twice daily)
†Results may vary.
New and Exciting Lyme Disease Research
By Lyn Hanshew, M.D.
Some of the most ill people I have tried to help have been diagnosed with Lyme disease. Conventionally, the diagnostic and treatment options are not good. Serological testing has been disappointing and confusing.
The difficulties with long-term antibiotic protocols include the expense, immune suppression, lack of insurance coverage, side-effects, potential for development of resistance and lack of studies demonstrating efficacy.
Countless people needlessly suffer from Lyme disease. After years of research I now present what I believe to be the most effective Lyme disease immune support system offered today.
Understanding the Cause of Lyme Disease
Lyme disease was first recognized in 1975 when mothers in Lyme, Connecticut, notified researchers that many of their children had been diagnosed with rheumatoid arthritis. Dr. Burgdorfer in 1981 discovered the spirochete Borellia burgdorferi that was transmitted from the deer tick to humans. In the US alone, over 300,000 new cases of Lyme disease are reported annually. It is the number one, vector-borne illness in the US, and is rapidly advancing worldwide. Lyme disease is difficult to diagnose due to inconsistent lab test results and patient history that may or may not include a known tick bite or bull’s eye lesion, arthritis, muscle weakness, memory loss and mood disorders including depression and anxiety.
References
1. Burgdorfer, William. “From Penicillin to Mild Silver Protein-An Answer to Lyme Disease Without Antibiotics”. Rocky Mountain Labortories, Division of N.I.H.
2. Cairns V, Godwin J (2005). “Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms”. Int J Epidemiol 34 (6): 1340–1345.
3. Singh SK, Girschick HJ (July 2004). “Lyme borreliosis: from infection to autoimmunity”. Clin. Microbiol. Infect. 10 (7): 598–614.
4. Stricker RB (July 2007). “Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease”. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 (2): 149–57.
5. Klempner MS, Hu LT, Evans J, et al. (July 2001). “Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease”. N. Engl. J. Med. 345 (2): 85–92.
6. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA (March 2008). “A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy”. Neurology 70 (13): 992–1003.
7. Krupp LB, Hyman LG, Grimson R, et al. (24 June 2003). “Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial”. Neurology 60 (12): 1923–30.
8. Feder HM, Johnson BJ, O’Connell S, et al. (October 2007). “A critical appraisal of “chronic Lyme disease””. N. Engl. J. Med. 357 (14): 1422–30.
9. Steere AC, Sikand VK, Schoen RT, Nowakowski J (2003). “Asymptomatic infection with Borrelia burgdorferi”. Clin. Infect. Dis. 37 (4): 528–532.
10. Fahrer H, Sauvain MJ, Zhioua E, Van Hoecke C, Gern LE (1998). “Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?”. Eur. J. Epidemiol. 14 (2): 117–123.
11. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC (March 2002). “Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans”. Ann. Intern. Med. 136 (6): 421–428.
12. Auwaerter PG, Aucott J, Dumler JS (January 2004). “Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment”. Expert Rev Mol Med 6 (2): 1–22.
13. Steere AC, Dhar A, Hernandez J, et al. (January 2003). “Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease”. Am. J. Med. 114 (1): 58–62.
14. Dandache P, Nadelman RB (June 2008). “Erythema migrans”. Infect. Dis. Clin. North Am. 22 (2): 235–60.Stanek G, Strle F (June 2008). “Lyme disease: European perspective”. Infect. Dis. Clin. North Am. 22 (2): 327–39.
15. Chabria SB, Lawrason J (2007). “Altered mental status, an unusual manifestation of early Disseminated Lyme disease: A case report”. Journal of Medical Case Reports 1 (1): 62.
16. Shadick NA, Phillips CB, Sangha O, et al. (December 1999). “Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease”. Ann. Intern. Med. 131 (12): 919–26.
17. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (February 2000). “Long-term outcomes of persons with Lyme disease”. JAMA 283 (5): 609–16.
18. Hess A, Buchmann J, Zettl UK, et al. (1999). “Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenia-like disorder”. Biol. Psychiatry 45 (6): 795.
19. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289– 300, vi–vii.
20. Mullegger RR (2004). “Dermatological manifestations of Lyme borreliosis”. Eur J Dermatol 14 (5): 296–309.
21. Tilly K, Rosa PA, Stewart PE (June 2008). “Biology of infection with Borrelia burgdorferi”. Infect. Dis. Clin. North Am. 22 (2): 217–34,
22. Lo Re V, Occi JL, MacGregor RR (April 2004). “Identifying the vector of Lyme disease”. Am Fam Physician 69 (8): 1935–7.
23. Steere AC (July 2001). “Lyme disease”. N. Engl. J. Med. 345 (2): 115–25.
24. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289–300, vi–vi.
25. Tylewska-Wierzbanowska S, Chmielewski T. (Jul 2002) “Limitation of serological testing for Lyme borreliosis evaluation of ELISA and western blot in comparison with PCR and culture methods”. Wien Klin Wochenschr 114(13- 14):601-5.
FAQ for Ultimate Immune Support System
1. What are the sizes of the bottles and how long do they last?
All products are 4 oz formulas and provide 60 days of support when administered at the standard dose (6 sprays, twice daily).
† Results may vary.
Reviews
There are no reviews yet.